Sinalização JAK/STAT
Os inibidores da sinalização JAK/STAT são compostos que interrompem a via da Janus quinase (JAK) e do transdutor e ativador da transcrição (STAT), que está envolvida na sinalização de citocinas, crescimento celular e resposta imunológica. Esses inibidores são ferramentas importantes para estudar a regulação dessa via e seu papel em diversas doenças, incluindo cânceres, distúrbios imunológicos e condições inflamatórias. Os inibidores de JAK/STAT também estão sendo desenvolvidos como terapias direcionadas para essas doenças. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de sinalização JAK/STAT de alta qualidade para apoiar sua pesquisa em biologia molecular, oncologia e imunologia.
Subcategorias de "Sinalização JAK/STAT"
Produtos da "Sinalização JAK/STAT"
Ordenar por
JAK3i
CAS:JAK3i selectively inhibits JAK3 kinase, targeting the second, vital wave of STAT5 phosphorylation for T cell growth.Fórmula:C18H15FN4O3Pureza:98.61% - 99.81%Cor e Forma:SolidPeso molecular:354.34PIM-1 Inhibitor 2
CAS:PIM-1 Inhibitor 2 (PIM1-IN-2) is a potent Pim-1 inhibitor with potential anti-cancer activity, used in cancer research.Fórmula:C17H11ClN4OPureza:98.81%Cor e Forma:SolidPeso molecular:322.75Solcitinib
CAS:Solcitinib (GLPG-0778), a JAK1 inhibitor, may treat psoriasis, ulcerative colitis, and lupus.Fórmula:C22H23N5O2Pureza:99.61% - 99.82%Cor e Forma:SolidPeso molecular:389.45TCS-PIM-1-4a
CAS:SMI-4a, a Pim inhibitor, activates AMPK, halts mTORC1, and kills various myeloid/lymphoid cells (IC50=0.8-40μM).Fórmula:C11H6F3NO2SPureza:99.89%Cor e Forma:SolidPeso molecular:273.23JAK-IN-29
JAK-IN-29 (Compound 3) is a potent inhibitor of Janus kinases (JAK) [1].Fórmula:C17H14ClN5O2Pureza:98%Cor e Forma:SolidPeso molecular:355.78JAK3/BTK-IN-1
CAS:JAK3/ BTk-in-1 is a dual JAK3/BTK inhibitor that specifically targets and inhibits Janus kinase 3 (JAK3) and Bruton's tyrosine kinase (BTK), two importantFórmula:C25H28N8OPureza:97.89%Cor e Forma:SolidPeso molecular:456.54Ruxolitinib phosphate
CAS:Ruxolitinib phosphate (INCB18424 phosphate) is a JAK1/2 inhibitor with IC50 of 3.3 nM/2.8 nM. Cost-effective and quality-assured.Fórmula:C17H21N6O4PPureza:100% - 99.91%Cor e Forma:SolidPeso molecular:404.36Ref: TM-T3043
1g615,00€5mg52,00€10mg65,00€25mg82,00€50mg97,00€100mg145,00€200mg227,00€500mg418,00€1mL*10mM (DMSO)59,00€PIM1-IN-4
CAS:PIM1-IN-4: strong PIM1 inhibitor, also blocks SGK-1, PKA, CaMK-1, GSK3β, MSK1; promising for cancer studies.Fórmula:C27H25BrCl2CuN6OPureza:98%Cor e Forma:SolidPeso molecular:663.88Deucravacitinib
CAS:Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable, allosteric TYK2 inhibitor.Cost-effective and quality-assured.Fórmula:C20H19D3N8O3Pureza:100% - 99.43%Cor e Forma:SolidPeso molecular:425.46Ref: TM-T14687
1mg70,00€5mg153,00€10mg274,00€25mg432,00€50mg638,00€100mg908,00€200mg1.225,00€500mg1.825,00€1mL*10mM (DMSO)166,00€GDC-0214
CAS:GDC-0214 is an inhaled small-molecule JAK1 inhibitor and reduces fractional exhaled nitric oxide (Feno).Fórmula:C28H28ClF2N9O3Pureza:98.54%Cor e Forma:SolidPeso molecular:612.03Ref: TM-T9826
1mg87,00€5mg192,00€10mg284,00€25mg452,00€50mg645,00€100mg867,00€200mg1.159,00€1mL*10mM (DMSO)259,00€AMG-47a
CAS:AMG-47a inhibits Lck, T cell growth, and degrades KRAS oncoprotein, affecting EGFP-KRASG12V but not EGFP.Fórmula:C29H28F3N5O2Pureza:98%Cor e Forma:SolidPeso molecular:535.56JAK2-IN-4
CAS:JAK2-IN-4 is a selective JAK2/JAK3 inhibitor, with IC50 values of 0.7 nM and 23.2 nM for JAK2 and JAK3, respectively.Fórmula:C23H27N5O4SPureza:98%Cor e Forma:SolidPeso molecular:469.56JAK3-IN-1
CAS:JAK3-IN-1 is an orally active, selective and potent JAK3 inhibitor for the study of immune system disorders.Fórmula:C26H30ClN7O2Cor e Forma:SolidPeso molecular:508.02Ruxolitinib
CAS:Ruxolitinib (INCB018424) is a JAK1/2 inhibitor (IC50=3.3/2.8 nM) that is potent and selective.Fórmula:C17H18N6Pureza:100% - 99.99%Cor e Forma:SolidPeso molecular:306.36Ref: TM-T1829
5mg58,00€10mg74,00€25mg92,00€50mg116,00€100mg155,00€200mg245,00€500mg414,00€1mL*10mM (DMSO)65,00€NVP-BSK805
CAS:NVP-BSK805 (BSK 805) is an ATP-competitive JAK2 inhibitor.Fórmula:C27H28F2N6OPureza:98%Cor e Forma:SolidPeso molecular:490.55SHR0302
CAS:SHR0302 (ARQ252) is a JAK inhibitor that binds JAK1 with stronger affinity than others (Selectivity for JAK1 is more than 10 times for JAK2, 77 times for JAK3,Fórmula:C18H22N8O2SPureza:99.11%Cor e Forma:SolidPeso molecular:414.48Ref: TM-T9195
1mg160,00€5mg393,00€10mg620,00€25mg1.035,00€50mg1.483,00€100mg1.882,00€1mL*10mM (DMSO)455,00€lirucitinib
CAS:Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.Fórmula:C16H25N5OSCor e Forma:SolidPeso molecular:335.468Antitumor agent-195
Antitumor agent-195 (compound 16c) is a dual-targeting agent that simultaneously targets STAT3 and NQO1. At a concentration of 1 μM, it significantly inhibits the phosphorylation of STAT3 at the Tyr705 site and effectively induces apoptosis in MDA-MB-231 and MDA-MB-468 breast cancer cells. As a substrate of NQO1, Antitumor agent-195 markedly increases ROS production, causing severe DNA damage in a dose-dependent manner. It also demonstrates strong antitumor properties in MDA-MB-231 xenograft models.Fórmula:C22H22N2O4Cor e Forma:SolidPeso molecular:378.42AZD1208
CAS:AZD1208 is a novel, orally bioavailable, highly selective PIM kinase inhibitor with single nanomolar potency against all three PIM kinases.Fórmula:C21H21N3O2SPureza:97.24% - 99.83%Cor e Forma:SolidPeso molecular:379.48Ref: TM-T2300
2mg38,00€5mg51,00€10mg74,00€25mg118,00€50mg213,00€100mg378,00€200mg495,00€500mg792,00€1mL*10mM (DMSO)57,00€JAK-IN-27
CAS:JAK-IN-27, also known as compound 1, is an orally active, potent inhibitor of the JAKS family kinases, displaying inhibitory concentrations (IC50s) of 3.0 nMFórmula:C20H21F2N7OPureza:98%Cor e Forma:SolidPeso molecular:413.42
